CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates

Shares of CorMedix (CRMD) rose nearly 30% on Tuesday after management announced fourth-quarter and full-year 2024 preliminary sales figures.CorMedix’s Preliminary Sales Figures Beat EstimatesCorMedix reported preliminary net revenues of nearly $31 million for the fourth quarter of 2024. This unaudited figure significantly beat the Zacks Consensus Estimate of $21.5 million. Based on these figures, management expects adjusted EBITDA for the quarter to exceed $12 million.For the full year, management reported ...